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IT’S ALL IN THE DETAILS 36 
Osuga and co-workers report the results of a randomized, double-blind, placebo-controlled trial on 37 
the effect of relugolix, 40 mg/day for 12 weeks, in women with pelvic pain associated with uterine 38 
fibroids (1). Sixty-five women with a maximum numerical rating scale score of ≥4 during 1 39 
menstrual cycle or other pain symptoms associated with uterine fibroids (e.g., lower abdominal or 40 
low back pain) for ≥2 days during 1 menstrual cycle, were recruited. The primary endpoint was the 41 
proportion of patients with a maximum score of ≤1 during the 28-day period before the final dose of 42 
the study drug. Almost six women out of 10 achieved this outcome (57.6%) in the experimental 43 
group versus almost none in the placebo group (3.1%). After 12 weeks of relugolix treatment the 44 
median fibroid and uterine volume reduction was 37% and 42%, respectively. More women in the 45 
relugolix group experienced untoward effects, especially hot flushes. 46 
 Pelvic pain, which is not the most frequent and clinically important symptom associated 47 
with uterine fibroids, here had to occur specifically during menstruation. The rapid inhibition of 48 
pituitary gonadotropins’ release induced by relugolix, leads to anovulation, reduction of serum E2 49 
to postmenopausal levels, amenorrhea and thus, by definition, relief of pain experienced during or 50 
exacerbated by menstruations. As placebos generally do not induce amenorrhea, the results of this 51 
trial were predictable. Moreover, it may not be excluded that some participants were suffering from 52 
undetected endometriosis rather than allegedly symptomatic fibroids.  53 
 According to the authors, “blind maintenance was achieved by concealment of the 54 
pharmacodynamics test results from all outside parties and personnel involved in the conduct of the 55 
study until the randomization code was opened”. However, the altered menstrual pattern and the 56 
typical vasomotor symptoms associated with relugolix use, renders this measure insufficient to 57 
ensure masking of treatment allocation. 58 
 The use of analgesics was restricted. Presumably, this favored the experimental group and it 59 
would have been interesting to know what would have happened had analgesics be used without 60 
restrictions. Only 5.4% of the women allocated to placebo used analgesics in the last month of the 61 
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study. This is somewhat unexpected, considering that the main selection criterion was precisely 62 
pain 63 
 64 
ARE GnRH ANTAGONISTS SUPERIOR TO GnRH AGONISTS? 65 
The present trial demonstrates that relugolix is effective in women with fibroids whose main 66 
presenting symptom is pelvic pain. However, behind registration purposes, some authors question 67 
the appropriateness of placebo-controlled studies when an effective treatment has already been 68 
established (3,4), and women with symptomatic fibroids might be more interested in understanding 69 
the added benefits of relugolix over the GnRH agonists they can currently use.  70 
Relugolix was compared with leuprorelin in a non-inferiority trial conducted on patients 71 
with fibroid-associated menorrhagia (4). Relugolix was associated with an earlier reduction in the 72 
amount of uterine bleeding and a faster recovery of menses after drug discontinuation. All the other 73 
outcomes were substantially similar in the two study groups, including the proportion of women 74 
achieving amenorrhea, increase in hemoglobin levels, reduction in fibroid and uterine volume, 75 
incidence and type of untoward effects, degree of bone mineral density loss, and improvements in 76 
health-related quality of life.  77 
 Relugolix is clearly a novel drug from a pharmacologic viewpoint, but is the rapidity in the 78 
onset and termination of action enough to define this and other GnRH antagonists really novel with 79 
respect to GnRH agonists in terms of clinical effectiveness? A faster onset of action can be 80 
beneficial in case of severe bleeding, and a faster termination of action is advantageous if 81 
intolerable untoward effects arise. In other cases, such differences may result of limited importance. 82 
 Much emphasis is being put on avoidance of the flare-up phase when using GnRH 83 
antagonists instead of agonists, but the practical impact of this few-day endocrine drawback on the 84 
outcome of a treatment enduring months is difficult to quantify. Moreover, the initial pituitary 85 
stimulation can be mitigated by injecting leuprorelin during the luteal phase. 86 
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 According to Mauri and D’Agostino a non-inferiority trial is justified when a new treatment 87 
“promise greater safety or convenience, or less expense, while providing similar efficacy”. (3) With 88 
regard to convenience, i.e., once daily oral versus once monthly intramuscular use, individual 89 
preferences seem predominant. Thus, in light of the similar efficacy and safety of GnRH agonists 90 
and antagonists, the choice of relugolix would be justified by a lower cost compared with that of 91 
leuprorelin. Indeed, a reduction in health care cost could determine the overall value of specific 92 
medical interventions (5). Will this be the case? 93 
 94 
SHORT-TERM OR LONG-TERM THERAPY? 95 
The mean participants’ age in the two study groups was between 40 and 42 years. When 96 
considering a medical therapy for symptomatic fibroids in women in their early forties, one crucial 97 
issue is to comprehend if this will be a short-term preoperative measure or, alternatively, a long-98 
term treatment aimed at avoiding surgery and reaching the physiologic menopause. 99 
 As the final common mechanism of action of GnRH antagonists and agonists is the same, 100 
i.e., induced hypoestrogenism, relugolix exerts most likely only temporary effects on fibroid-101 
associated symptoms and lesions’ dimension. In this case, fibroid re-growth and symptoms’ 102 
reappearance are anticipated soon after drug discontinuation. Therefore, once the efficacy of 103 
relugolix has been demonstrated in trials of a few-month duration, the obvious question that arises 104 
is “what to do next”? 105 
 Trials on treatment of women with symptomatic fibroids with relugolix plus add-back 106 
therapy for up to 2 years are ongoing. The definitive objective of this type of studies should be to 107 
verify whether medical therapy could be considered a clinically effective and cost-effective 108 
alternative to surgery. Here the appropriate active comparator is either myomectomy or 109 
hysterectomy.  110 
 111 
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 Controlling indefinitely fibroid growth, menorrhagia, and pelvic pain by modulating ovarian 112 
steroid production seems an attractive option for many women. However, clinical effectiveness and 113 
cost-effectiveness of long-term GnRH antagonist therapy may vary considerably depending on 114 
baseline patient conditions and duration of treatment. The balance may be tipped toward medical 115 
therapy in patients at high surgical risk and in those who, presumably, are close to menopause. 116 
However, in younger women the cost and the potential disadvantages of the medical choice increase 117 
in parallel with the expected duration of treatment.  118 
 Hysterectomy for symptomatic fibroids is associated with a high degree of patient 119 
satisfaction, and morbidity and social costs of surgery are reduced when the procedure is carried out 120 
at laparoscopy or vaginally. In premenopausal women, ovarian sparing allows continuation of 121 
gonadal function. Moreover, systematic opportunistic salpingectomy might substantially reduce the 122 
risk of epithelial ovarian cancer.  123 
 124 
“WHAT IS AND WHAT SHOULD NEVER BE” * 125 
*Page J, Plant R. In Led Zeppelin II. Atlantic Records, U.K., 1969 126 
 127 
According to Wieseler et al. (4) only a limited proportion of new drugs provide real advances over 128 
existing ones. Regulators should require evidence from large, superiority, active controlled trials to 129 
allow clinical effectiveness comparison and health technology assessment, and inform health care 130 
policy. The German Institute for Quality and Efficiency in Health Care categorizes as minor, 131 
considerable or major the added benefit of any new drug compared with available drugs, based on 132 
importance of the outcome and magnitude of the effect. Reimbursement and pricing decisions 133 
should reward achievement of relevant outcomes for patients, disincentivizing marginal ones (4). 134 
 Incremental cost-effectiveness ratios (ICER) should be used to weigh trade-offs between 135 
health outcomes and costs and identify those medical interventions that improve the health of 136 
patients marginally and are not worth the additional costs required (5). This seems important not 137 
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only with reference to the final price of relugolix and other GnRH antagonists compared with 138 
available GnRH agonists, but also in case of modifications of current indications to medical 139 
treatment for fibroids.  140 
 For example, in Europe in the past years the indication for ulipristal acetate expanded from a 141 
single preoperative course, to multiple courses up to 18 months of treatment as an alternative to 142 
surgery. The European Medicine Agency authorized this indication extension without data 143 
originating from trials including an active comparator such as a depot GnRH agonist plus add-back 144 
therapy or surgery.  145 
 Other potential risks associated with the marketing of new drugs for fibroids include 146 
broadening of disease definitions (e.g., pelvic pain or sexual dysfunction not necessarily caused by 147 
fibroids) and lowering the bar for a medical intervention (e.g., prescribing a medication when 148 
surgery would not be required). Moreover, would the frequency of well-women transvaginal 149 
sonographies be increased to detect small asymptomatic fibroids to be treated medically before they 150 
become so large to necessitate surgery or supposedly jeopardize future fertility (secondary 151 
prevention)? Would women who underwent myomectomy be invited to use GnRH antagonists to 152 
limit the risk of postoperative recurrence (tertiary prevention)? 153 
 Relugolix constitutes an important additional short-term medical option to correct anemia 154 
and, when indicated, reduce fibroid and uterine volume before surgery. Ongoing trials will clarify 155 
whether long-term use of relugolix plus add-back therapy could be suggested in patients at 156 
increased surgical risk. But only comparative effectiveness research and health technology 157 
assessment, preferably conducted by independent investigators, might define the number needed to 158 
treat and ICER relative to relugolix use in other clinical conditions.  159 
 160 
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